Novel Therapies and Monitoring in Cholestatic Disease

Nov 10 2025
Convention Center: Room 145, Level 1
2:00 PM - 3:30 PM

World Class Speakers

Craig Lammert, MD, MS
Abstract Presenter

Craig Lammert, MD, MS

Indiana University School of Medicine
Bishoi Aziz, MD, MSc
Abstract Presenter

Bishoi Aziz, MD, MSc

Western Ontario University
Andreas E. Kremer, MD, PhD
Abstract Presenter

Andreas E. Kremer, MD, PhD

University of Zurich
Maria Serena Longhi, MD, PhD
Abstract Presenter

Maria Serena Longhi, MD, PhD

Beth Israel Deaconess Medical Center
Gideon M Hirschfield, FRCP, PhD
Moderator

Gideon M Hirschfield, FRCP, PhD

Toronto General Hospital
Maria Serena Longhi, MD, PhD
Moderator

Maria Serena Longhi, MD, PhD

Beth Israel Deaconess Medical Center

Description

This abstract parallel session features a series of reports on the exploration of new agents in AIH and PBC, along with intriguing data on enhanced monitoring in cholestatic disorders.  

Journey Maps

Presentations

2:00 PM - 2:15 PM
Aug 06 2026
Convention Center - Room 145, Level 1

Zetomipzomib, a First-in-Class Selective Immunoproteasome Inhibitor, Demonstrates Steroid Sparing Biochemical Remission in Patients with Relapsed or Insufficiently Responding Autoimmune Hepatitis in a Randomized, Double-blind, Placebo-controlled, Phase 2a Study

Craig Lammert, MD, MS , Abstract Presenter
Cholestatic and Autoimmune
2:15 PM - 2:30 PM
Aug 06 2026
Convention Center - Room 145, Level 1

Machine Learning Prognostic Model Predicts All-Cause Mortality or Liver Transplant in Patients with Autoimmune Hepatitis

Bishoi Aziz, MD, MSc , Abstract Presenter
Cholestatic and Autoimmune
2:30 PM - 2:45 PM
Aug 06 2026
Convention Center - Room 145, Level 1

Seladelpar Is Associated With a Sustained Reduction in Cholestatic Markers and a Consistent Safety Profile in Patients With Primary Biliary Cholangitis Treated up to 48 Months in the Ongoing, Open-Label ASSURE Study

Andreas E. Kremer, MD, PhD , Abstract Presenter
Cholestatic and Autoimmune
2:45 PM - 3:00 PM
Aug 06 2026
Convention Center - Room 145, Level 1

Impact of linerixibat on pharmacodynamic biomarkers and mediators of cholestatic pruritus in primary biliary cholangitis (PBC) in the Phase 3 GLISTEN study 

Andreas E. Kremer, MD, PhD , Abstract Presenter
Cholestatic and Autoimmune
3:15 PM - 3:30 PM
Aug 06 2026
Convention Center - Room 145, Level 1

Validating Liver Stiffness Measurement in Predicting Outcomes in Primary Sclerosing Cholangitis: An International Cross-Centre Study of More Than 1000 Patients

Maria Serena Longhi, MD, PhD , Abstract Presenter
Cholestatic and Autoimmune

Objectives

  • Describe the complexities and options for AIH treatments.
  • Discuss the potential roles for PPAR modulation in PBC.
  • Identify the potential roles for IBAT targeting in cholestasis.